Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B5HS
|
|||
| Former ID |
DNCL003647
|
|||
| Drug Name |
NLG8189
|
|||
| Synonyms |
1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2/3 | [1], [2] | |
| Pancreatic cancer [ICD-11: 2C10; ICD-9: 185] | Phase 2 | [1] | ||
| Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [1] | ||
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1] | ||
| Brain cancer [ICD-11: 2A00] | Phase 1 | [1] | ||
| Company |
NewLink Genetics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H14N2O2
|
|||
| Canonical SMILES |
CN1C=C(C2=CC=CC=C21)CC(C(=O)O)N
|
|||
| InChI |
1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16)/t10-/m1/s1
|
|||
| InChIKey |
ZADWXFSZEAPBJS-SNVBAGLBSA-N
|
|||
| CAS Number |
CAS 110117-83-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
536240, 10283807, 12015926, 24698450, 24868706, 35565652, 47944065, 57402457, 74441384, 88835906, 99373845, 103101565, 103707643, 104178863, 104595796, 117477495, 117541991, 129873353, 131294358, 135267136, 135585016, 136910775, 136991426, 139261644, 144190993, 151990172, 152037882, 152164678, 152245734, 162121641, 162185384, 162243338, 162475474, 164223395, 174007490, 179236062, 198978805, 202539264, 204421731, 223519682, 223889661, 227196742, 249565906, 249781116, 249804675, 250166679
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target Info | Inhibitor | [1], [2] |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation | ||||
| L-kynurenine degradation | ||||
| Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde | ||||
| NAD de novo biosynthesis | ||||
| KEGG Pathway | Tryptophan metabolism | |||
| Metabolic pathways | ||||
| African trypanosomiasis | ||||
| NetPath Pathway | TSLP Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Tryptophan Metabolism | |||
| Reactome | Tryptophan catabolism | |||
| WikiPathways | Tryptophan metabolism | |||
| Metabolism of amino acids and derivatives | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.